Bicycle Therapeutics

United Kingdom
Cambridge, England, United Kingdom, CB22 3AT

Company profile

Bicycle Therapeutics company profile

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Business identity

Contact email
[email protected]
Phone number
+44 1223 497 415
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Revenue range
$1M-$10M
Founded
2009-01-01, Year

Headquarters

Postal code
CB22 3AT
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
14
Total equity funding
$1B
Last funding
Post IPO Equity / $555M / 2024-05-23
Last equity funding
Post IPO Equity / $555M
Investors
21
Lead investors
3
Founders
2
Articles
186
Exited on
2019-05-23

Founders and investors

Founders

Christian HeinisGregory Winter

Lead investors

Innovate UKVenture KickVertex Ventures

Investors

Perceptive AdvisorsRA Capital ManagementSR OneSV Health InvestorsVertex Ventures